Biotech Scan
Biotech Scan
Biotech three-way split: life sciences tools (DHR RSI 29, MDT RSI 27, TMO RSI 35, A RSI 31) in coordinated selloff, BNTX capitulating at RSI 23 with -23.3% 30D collapse, while MRNA rockets +85.6% 3M and large-cap pharma (ABBV, AMGN, REGN) stays boring — and ISRG/VRTX quietly anchor the quality compounders.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 MIXED — Life sciences tools (DHR, MDT, TMO, A) entering oversold territory as a group, BNTX in mRNA capitulation, while MRNA surges on opposite side of mRNA trade; large-cap pharma stable; surgical/medtech (ISRG, DXCM) drifting lower |
| Leaders | MRNA (+35.7% 30D, +85.6% 3M), EDIT (+49.2% 30D), PTGX (+16.2% 30D), NTLA (+12.3% 30D), VRTX (+8.2% 30D) |
| Laggards | DNA (-32.2% 30D), BNTX (-23.3% 30D, RSI 23), NVO (-20.6% 30D), MDT (-11.1% 30D, RSI 27), DHR (-11.3% 30D, RSI 29) |
Price Table (2026-03-10)
| Stock | Price | RSI | SMA20 | vs SMA | 7D% | 30D% | Signal |
|---|---|---|---|---|---|---|---|
| ETFs | — | — | — | — | — | — | — |
| XBI | $127.43 | 54 | $125.81 | +1.3% | +1.8% | +2.2% | 🟢 Healthy |
| IBB | $172.27 | 49 | $172.94 | -0.4% | +0.4% | -0.3% | 🟡 Neutral |
| IBBQ | $29.56 | 51 | $29.60 | -0.1% | +0.5% | +0.4% | 🟡 Neutral |
| LABU | $171.50 | 53 | $166.58 | +3.0% | +5.0% | +5.0% | 🟢 Healthy |
| Large-Cap Pharma | — | — | — | — | — | — | — |
| ABBV | $227.01 | 49 | $228.80 | -0.8% | -2.9% | +2.8% | 🟡 Neutral |
| GILD | $148.56 | 55 | $149.40 | -0.6% | +0.3% | -4.7% | 🟡 Neutral |
| AMGN | $375.43 | 55 | $375.40 | +0.0% | -0.2% | +3.1% | 🟡 Neutral |
| REGN | $772.03 | 50 | $779.06 | -0.9% | -0.8% | -0.8% | 🟡 Neutral |
| BIIB | $188.41 | 51 | $190.99 | -1.3% | +0.8% | -1.5% | 🟡 Neutral |
| LLY | $1,001.35 | 45 | $1,020.94 | -1.9% | +0.2% | -1.2% | 🟡 Neutral — GLP-1 king drifting |
| VRTX | $499.17 | 60 | $475.96 | +4.9% | +5.0% | +8.2% | 🟢 Strong — leading pharma |
| mRNA | — | — | — | — | — | — | — |
| MRNA | $54.98 | 62 | $49.50 | +11.1% | +1.9% | +35.7% | 🟠 Extended — massive rally |
| NVO | $38.72 | 34 | $42.57 | -9.0% | +1.4% | -20.6% | 🔴 Breakdown |
| BNTX | $83.89 | 23 | $105.83 | -20.7% | -17.4% | -23.3% | 🔴 Capitulation |
| Gene Editing / Gene Therapy | — | — | — | — | — | — | — |
| CRSP | $52.80 | 45 | $55.30 | -4.5% | -11.6% | +9.3% | 🟡 Pullback after run |
| NTLA | $13.47 | 52 | $13.14 | +2.5% | -3.7% | +12.3% | 🟡 Recovering |
| BEAM | $26.08 | 44 | $27.75 | -6.0% | -6.5% | +0.4% | 🟡 Neutral |
| EDIT | $2.64 | 67 | $1.99 | +32.7% | +21.6% | +49.2% | 🟠 Near Overbought |
| LEGN | $19.56 | 56 | $18.59 | +5.2% | +10.1% | +5.5% | 🟢 Recovering |
| SRPT | $17.66 | 47 | $17.59 | +0.4% | +9.8% | -1.7% | 🟡 Bouncing |
| Genomics / Diagnostics | — | — | — | — | — | — | — |
| ALNY | $322.38 | 42 | $326.04 | -1.1% | +0.2% | +0.0% | 🟡 Neutral |
| BMRN | $60.89 | 54 | $61.05 | -0.3% | +3.1% | +1.0% | 🟡 Neutral |
| INCY | $96.02 | 39 | $99.73 | -3.7% | -1.7% | -2.9% | 🟡 Approaching Oversold |
| ILMN | $122.35 | 42 | $122.97 | -0.5% | -7.3% | +5.1% | 🟡 Neutral |
| EXAS | $103.37 | 56 | $103.37 | +0.0% | -0.1% | -0.1% | 🟡 Neutral |
| IONS | $75.66 | 38 | $80.70 | -6.2% | -3.6% | -10.3% | 🟡 Approaching Oversold |
| DXCM | $67.79 | 38 | $71.12 | -4.7% | -5.5% | -0.5% | 🟡 Approaching Oversold |
| Surgical / MedTech | — | — | — | — | — | — | — |
| ISRG | $485.85 | 40 | $495.86 | -2.0% | -3.2% | -2.1% | 🟡 Weakening |
| MDT | $89.89 | 27 | $96.72 | -7.1% | -6.6% | -11.1% | 🟢 Oversold |
| Tools / Services | — | — | — | — | — | — | — |
| DHR | $195.22 | 29 | $207.94 | -6.1% | -4.6% | -11.3% | 🟢 Oversold |
| TMO | $500.08 | 35 | $513.50 | -2.6% | -2.3% | -5.1% | 🟡 Approaching Oversold |
| A | $115.43 | 31 | $122.37 | -5.7% | -4.0% | -10.5% | 🟢 Approaching Oversold |
| IQV | $170.93 | 39 | $171.65 | -0.4% | -3.1% | -3.5% | 🟡 Neutral |
| Small-Cap / Speculative | — | — | — | — | — | — | — |
| PTGX | $97.05 | 67 | $88.06 | +10.2% | +4.5% | +16.2% | 🟠 Near Overbought |
| DNA | $6.34 | 34 | $8.19 | -22.6% | -8.0% | -32.2% | 🔴 Breakdown |
| RXRX | $3.44 | 40 | $3.58 | -4.0% | -7.5% | -7.3% | 🟡 Weak |
| RARE | $22.84 | 48 | $22.35 | +2.2% | +4.4% | -4.4% | 🟡 Neutral |
| BLUE | N/A | — | — | — | — | — | — No Data |
| SWTX | N/A | — | — | — | — | — | — No Data |
Tier Analysis
Oversold (RSI < 30) — Capitulation Territory
BNTX (RSI 23, -23.3% 30D, -20.7% below SMA20) — mRNA sentiment washout in full force. Price at $83.89 vs SMA20 of $105.83 is an enormous gap. The -17.4% 7D acceleration confirms active capitulation, not just drift. Either a contrarian entry or thesis collapse on mRNA demand post-COVID. MDT (RSI 27, -11.1% 30D, -7.1% below SMA20) — Medtronic, a medtech stalwart, rarely sees RSI sub-30. At $89.89 down -9.2% 3M, this looks like forced selling or rotation pressure rather than fundamental deterioration. DHR (RSI 29, -11.3% 30D, -6.1% below SMA20) — Danaher life sciences tools bellwether entering oversold. Quality compounder at $195.22, down -15.9% 3M. When DHR hits RSI 29, historically that's been a strong entry signal.
Approaching Oversold (RSI 30-40) — Watch Closely
A (RSI 31, -10.5% 30D, -19.1% 3M) — Agilent tracking DHR lower. Life sciences tools getting hit sector-wide — this isn't stock-specific. NVO (RSI 34, -20.6% 30D, -53.1% from 52-week high) — Novo Nordisk GLP-1 giant in secular decline from highs. RSI 34 with a small +1.4% 7D bounce, not yet stabilizing. DNA (RSI 34, -32.2% 30D, -36.0% 3M, -63.9% from high) — Ginkgo in freefall, no stabilization in sight. TMO (RSI 35, -5.1% 30D, -13.6% 3M) — Thermo Fisher tracking DHR lower, confirming the life sciences tools de-rating is sector-wide. DXCM (RSI 38, -0.5% 30D, -24.7% from high) — DexCom continuous glucose monitoring drifting, -5.5% 7D. GLP-1 overhang weighing on diabetes devices. IONS (RSI 38, -10.3% 30D) — Ionis antisense platform weakening. INCY (RSI 39, -2.9% 30D) — Incyte drifting lower, not urgent but monitoring. RXRX (RSI 40, -24.9% 3M, -52.1% from high) — Recursion AI-bio play still bleeding. IQV (RSI 39, -3.5% 30D, -24.4% 3M) — IQVIA sustained downtrend on 3M basis. ISRG (RSI 40, -2.1% 30D, -19.6% from high) — Intuitive Surgical drifting toward oversold. Quality surgical robotics monopoly weakening from extended levels — watch for RSI <35 entry.
Neutral (RSI 40-55) — Holding Ground
Large-cap pharma cluster: ABBV (RSI 49), REGN (RSI 50), BIIB (RSI 51), AMGN (RSI 55), GILD (RSI 55), LLY (RSI 45) — all within a tight 45-55 RSI band, all near their SMA20s. This group is doing exactly what defensive pharma should: boring, stable, thesis intact. LLY at $1,001.35 is the GLP-1 king, only -1.2% 30D vs NVO's -20.6% — massive divergence. Also here: ALNY (RSI 42), BEAM (RSI 44), CRSP (RSI 45), ILMN (RSI 42), SRPT (RSI 47), RARE (RSI 48), NTLA (RSI 52), EXAS (RSI 56), BMRN (RSI 54), LEGN (RSI 56), LABU (RSI 53), XBI (RSI 54), IBB (RSI 49), IBBQ (RSI 51).
Extended (RSI > 60) — Don't Chase
EDIT (RSI 67, +49.2% 30D, +32.7% above SMA20) — Massively extended on a sub-$3 stock. At $2.64 this is pure speculation. The +49.2% 30D move on a stock -41.8% from its 52-week high screams dead-cat bounce. PTGX (RSI 67, +16.2% 30D, +10.2% above SMA20) — Protagen clinical-stage autoimmune play near 52-week highs (-1.2% from high). More fundamentally grounded than EDIT but still extended. MRNA (RSI 62, +35.7% 30D, +85.6% 3M, +11.1% above SMA20) — The mRNA comeback story. MRNA surging while BNTX capitulates — sharp divergence within the same subsector. At $54.98, still -7.7% from 52-week high but momentum is powerful. Don't chase here; wait for a consolidation. VRTX (RSI 60, +8.2% 30D, +4.9% above SMA20) — Vertex Pharmaceuticals quietly leading. Only -4.0% from 52-week high. Quality franchise trending right, but extended.
Entry Zones
| Stock | Entry Zone | Thesis |
|---|---|---|
| ✅ DHR | $185-$200 | RSI 29, life sciences tools bellwether. Quality compounder at -15.9% 3M. Historically strong entry when RSI dips below 30. |
| ✅ MDT | $85-$92 | RSI 27, defensive medtech oversold. Unusual for this name — likely rotation-driven, not fundamental. |
| 🔍 BNTX | $75-$85 | RSI 23 capitulation. mRNA thesis needs validation — is this cycle trough or structural decline? |
| 🔍 TMO | $480-$505 | RSI 35, tracking DHR in tools selloff. Quality franchise at -13.6% 3M. Wait for RSI <30 for highest conviction. |
| 🔍 A | $110-$118 | RSI 31, approaching oversold. Life sciences tools sector-wide de-rating. Quality on sale. |
| 🔍 NVO | $35-$40 | RSI 34, -53% from highs. GLP-1 mega-theme under pressure. Potential generational entry if competitive moat intact. |
| 🔍 ISRG | $460-$490 | RSI 40, surgical robotics monopoly weakening. Watch for RSI <35 for strong entry. -19.6% from high. |
| 🔍 DXCM | $62-$68 | RSI 38, -24.7% from high. GLP-1 overhang on diabetes devices. Needs thesis clarity on device vs drug dynamic. |
| 📈 LLY | $950-$1,000 | RSI 45, GLP-1 king holding far better than NVO (-1.2% 30D vs -20.6%). Core franchise. |
| 📈 LEGN | $18-$21 | RSI 56, recovering from -57% capitulation. CAR-T play showing momentum (+10.1% 7D, +5.5% 30D). |
| 📈 CRSP | $48-$54 | RSI 45, gene editing leader. Pulled back -11.6% 7D after +9.3% 30D run — healthy consolidation. |
| 🔍 RARE | $20-$24 | RSI 48, -36.9% 3M, -46.1% from highs. Rare disease pipeline optionality at deep discount. |
| ⚠️ EDIT | >$2.50 | RSI 67, +49.2% 30D — massively extended. Do not chase. Wait for consolidation below RSI 50. |
| ⚠️ PTGX | >$90 | RSI 67, +16.2% 30D — extended. Research clinical catalysts before entry. |
| ⚠️ MRNA | >$50 | RSI 62, +35.7% 30D, +85.6% 3M — massive run. Don't chase; wait for pullback to $45-48 range. |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ✅ STRONG BUY | DHR | RSI 29, quality compounder -15.9% 3M. Life sciences tools bellwether at oversold levels. |
| ✅ STRONG BUY | MDT | RSI 27, defensive medtech rarely this oversold. -11.1% 30D selloff looks like forced selling. |
| 🔍 RESEARCH | BNTX | RSI 23 capitulation — need to validate mRNA demand thesis before buying the dip. |
| 🔍 WATCH | TMO, A, NVO | RSI 31-35, approaching oversold. Quality names need stabilization signal before entry. |
| 🔍 WATCH | ISRG, DXCM | RSI 38-40, surgical/medtech weakening. Watch for RSI <35 entry trigger. |
| 🔍 WATCH | IONS, INCY, IQV | RSI 38-39, drifting lower. Monitor for oversold entry. |
| 📈 ACCUMULATE | LLY | RSI 45, GLP-1 king stable at $1,001. Holding far better than NVO. Core compounder. |
| 📈 ACCUMULATE | LEGN, CRSP, NTLA | Gene editing/therapy names recovering. LEGN +10.1% 7D, CRSP +9.3% 30D, NTLA +12.3% 30D. |
| 📈 ACCUMULATE | VRTX | RSI 60, quietly leading pharma. +8.2% 30D, only -4.0% from high. Quality franchise. |
| 🔒 HOLD | ABBV, AMGN, REGN, BIIB, GILD | Large-cap pharma RSI 49-55 — stable, defensive, boring. Thesis intact. |
| 🔒 HOLD | XBI, IBB, IBBQ, LABU | Sector ETFs neutral RSI 49-54. No conviction signal either way. |
| 🔒 HOLD | ALNY, BMRN, EXAS, ILMN | Mid-cap genomics/diagnostics RSI 42-56. Stable, no action needed. |
| ⚠️ AVOID | EDIT | RSI 67, +49.2% 30D on a sub-$3 micro-cap. Extended, high reversal risk. |
| ⚠️ AVOID | PTGX | RSI 67, +16.2% 30D — extended. Wait for pullback. |
| ⚠️ AVOID | MRNA | RSI 62, +35.7% 30D, +85.6% 3M — don't chase this rally. Wait for consolidation. |
| ❌ DON'T BUY | DNA | RSI 34, -32.2% 30D, -36.0% 3M, -63.9% from high. Falling knife, no stabilization. |
| ❌ DON'T BUY | RXRX | RSI 40, -24.9% 3M, -52.1% from high. Structural decline. |
| ❌ DON'T BUY | SRPT | RSI 47 but -82.9% from 52-week high. Gene therapy in deep structural distress. |
| — | BLUE, SWTX | No data available |
What Changed (vs previous scan)
| Change | Detail |
|---|---|
| NEW TICKERS: VRTX, LLY, MRNA, CRSP, NTLA, TMO, DXCM, ISRG | Expanded coverage — added GLP-1 king (LLY), mRNA comeback (MRNA), gene editing trio (CRSP, NTLA), life sciences tools (TMO), medtech (DXCM, ISRG), and pharma leader (VRTX). |
| MRNA vs BNTX divergence | MRNA +85.6% 3M (RSI 62) while BNTX -12.6% 3M (RSI 23). Same subsector, opposite trajectories. Market picking winners in mRNA. |
| LLY vs NVO divergence | LLY -1.2% 30D (RSI 45) while NVO -20.6% 30D (RSI 34). GLP-1 leadership gap widening dramatically. |
| TMO confirms tools selloff | TMO RSI 35 joins DHR (29), A (31), MDT (27) — four life sciences tools/services names all oversold or approaching it. Sector-wide, not stock-specific. |
| ISRG weakening | RSI 40, -19.6% from high. Surgical robotics monopoly drifting toward oversold — new watch candidate. |
| Gene editing recovering | CRSP +9.3% 30D, NTLA +12.3% 30D, LEGN +5.5% 30D — early signs of sector rotation into gene editing. |
| BNTX still capitulating | RSI 23 unchanged as deepest oversold. -17.4% 7D acceleration — selling is getting worse, not better. |
Key Discoveries
| Discovery | Implication |
|---|---|
| Four life sciences tools names (DHR RSI 29, MDT RSI 27, A RSI 31, TMO RSI 35) in coordinated selloff | Sector-wide de-rating, not stock-specific. Best entry opportunity in tools in months — buy the group, not the individual. |
| MRNA +85.6% 3M while BNTX -12.6% 3M | mRNA market is picking winners. MRNA pipeline diversification paying off; BNTX one-trick COVID pony thesis failing. |
| LLY -1.2% 30D vs NVO -20.6% 30D | GLP-1 leadership consolidating around LLY. Novo's competitive position eroding — Ozempic/Wegovy losing share to Mounjaro/Zepbound. |
| ISRG RSI 40, -19.6% from high | Surgical robotics monopoly weakening for first time — could become a Strong Buy if RSI hits <30. |
| Gene editing trio (CRSP/NTLA/LEGN) all positive 30D | Early rotation into gene editing. CRISPR Therapeutics has first approved gene therapy (Casgevy) — sector thesis strengthening. |
Mistakes (Don't Repeat)
| Mistake | Lesson |
|---|---|
| Previous scan lacked key names (LLY, MRNA, VRTX, ISRG, TMO) | Expanded watchlist now captures full biotech landscape. Missing LLY/NVO divergence and MRNA surge was a gap. |
Open Questions
- Is BNTX RSI 23 a buy or a value trap? Need to assess mRNA pipeline beyond COVID — what's the oncology pipeline worth?
- MDT rarely this oversold — what's driving the selloff? Earnings miss, GLP-1 weight loss reducing surgical volumes, or pure rotation?
- DHR + A + TMO + MDT all oversold together — buy the life sciences tools basket or wait for macro stabilization?
- MRNA +85.6% 3M — what changed? Pipeline catalyst, partnership, or short squeeze? Need deep dive before any position.
- ISRG drifting toward oversold — is GLP-1 weight loss a structural headwind for bariatric surgery volumes?
- CRSP/NTLA gene editing recovery sustainable, or just a bounce in speculative biotech?
Related
10 eventsNo direct external sources are attached to this read.